Symeres has been active in the field of lipid synthesis for pharmaceutical use since the 1990s and has significantly potentiated the platform with the 2022 acquisition of our Organix affiliate in Boston MA. With the development of novel mRNA-based therapeutics, there has been a rapid increase in the development of novel lipids and lipid technologies, especially since the outbreak of the COVID-19 pandemic. Symeres has been supporting the global pharma and biotech industry with the synthesis and (ultra)purification of these novel lipids.
Typically, mRNA-based vaccines rely on a lipid formulation to ensure stability and intracellular delivery. As a result, research centered around novel lipids has flourished. Lipid-based formulations of these biopharmaceuticals may provide better specificity for increased immune response and possible dose reduction. There is strong demand for high-quality lipids for drug delivery. At Symeres, we have actively been supporting the global pharma and biotech industry with the synthesis and (ultra)purification of such novel lipids. Our services range from designing and synthesizing new lipids to the development of processes to deliver significant amounts of ultrapure materials (also under GMP certification). Symeres has the equipment and know-how to purify and analyze these typically nonchromophoric molecules, including automated (reverse-phase) chromatography and preparative HPLC/SFC purification systems equipped with ELSD and CAD detection. Also, we can execute GC-FAME analysis.
In April 2022, Organix, based in Woburn MA, USA, was acquired by Symeres. Organix has a strong reputation for supplying high-quality lipids for research applications. Some of these lipids may be purchased directly from our stock catalogue (www.organixinc.com/lipids).
For your lipid needs, Symeres and Organix are your partner of choice. Contact our team of experts to learn more about what we can do for you.
